Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes

References

• Dunlay SM, Givertz MM, Aguilar D, et al., American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and the Heart Failure Society of America. Type 2 Diabetes Mellitus and Heart Failure: a Scientific Statement From the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–e324.
   PubMed Web of Science ®Google Scholar
• Sattar N, Rawshani A, Franzén S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation. 2019;139(19):2228–2237.
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Xanthopoulos A, Bargiota A, et al. Diabetes Mellitus and Heart Failure. J Clin Med. 2021;10(16):3682.
   PubMed Web of Science ®Google Scholar
• Ye H, He Y, Zheng C, et al. Type 2 diabetes complicated with heart failure: research on therapeutic mechanism and potential drug development based on insulin signaling pathway. Front Pharmacol. 2022;13:816588.
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E, Mikhailidis DP. Metformin and heart failure: never say never again. Expert Opin Pharmacother. 2012;13(1):1–8.
   PubMed Web of Science ®Google Scholar
• Salvatore T, Galiero R, Caturano A, et al. Effects of metformin in heart failure: from pathophysiological rationale to clinical evidence. Biomolecules. 2021;11(12):1834.
   PubMed Web of Science ®Google Scholar
• Papazafiropoulou A, Papanas N, Pappas S, et al. Effects of oral hypoglycemic agents on platelet function. J Diabetes Complications. 2015;29(6):846–851.
   PubMed Web of Science ®Google Scholar
• Sardu C, D’Onofrio N, Torella M, et al. Pericoronary fat inflammation and Major Adverse Cardiac Events (MACE) in prediabetic patients with acute myocardial infarction: effects of metformin. Cardiovasc Diabetol. 2019;18(1):126.
   PubMed Web of Science ®Google Scholar
• Sardu C, D’Onofrio N, Torella M, et al. Metformin therapy effects on the expression of sodium-glucose cotransporter 2, Leptin, and SIRT6 Levels in pericoronary fat excised from pre-diabetic patients with acute myocardial infarction. Biomedicines. 2021;9(8):904.
   PubMed Web of Science ®Google Scholar
• Sardu C, Paolisso P, Sacra C, et al. Effects of metformin therapy on coronary endothelial dysfunction in patients with prediabetes with stable angina and nonobstructive coronary artery stenosis: the CODYCE multicenter prospective study. Diabetes Care. 2019;42(10):1946–1955.
   PubMed Web of Science ®Google Scholar
• Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402.
   PubMed Web of Science ®Google Scholar
• Crowley MJ, Diamantidis CJ, McDuffie JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166(3):191–200.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Y, Min X, et al. The association between metformin treatment and outcomes in type 2 diabetes mellitus patients with heart failure with preserved ejection fraction: a retrospective study. Front Cardiovasc Med. 2021;8:648212.
   PubMed Web of Science ®Google Scholar
• Halabi A, Sen J, Huynh Q, et al. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19(1):124.
   PubMed Web of Science ®Google Scholar
• Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18(1):96.
   PubMedGoogle Scholar
• Cintra RM, Nogueira AC, Bonilha I, et al. Glucose-lowering drugs and hospitalization for heart failure: a systematic review and additive-effects network meta-analysis with more than 500.000 patient-years. J Clin Endocrinol Metab. 2021;106(10):3060–3067.
   PubMed Web of Science ®Google Scholar
• Li T, Providencia R, Mu N, et al. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):30.
   PubMed Web of Science ®Google Scholar
• Gu J, Yin ZF, Zhang JF, et al. Association between long-term prescription of metformin and the progression of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and hypertension. Int J Cardiol. 2020;306:140–145.
   PubMed Web of Science ®Google Scholar
• Wiggers H, Køber L, Gislason G, et al. The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): a 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). Am Heart J. 2021;231:137–146.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT05093959 Last accessed 28 June 2022
   Google Scholar
• Tahrani AA, Varughese GI, Scarpello JH, et al. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ. 2007;335(7618):508–512.
   PubMed Web of Science ®Google Scholar
• ADA. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl. 1):S125–S143.
   PubMedGoogle Scholar
• ESC Scientific Document Group, Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2):255–323.
   PubMed Web of Science ®Google Scholar
• Seferović PM, Coats AJS, Ponikowski P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020;22(2):196–213.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism. 2022;130:155160.
   PubMed Web of Science ®Google Scholar
• Nesti L, Tricò D, Mengozzi A, et al. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021;20(1):109.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289.
   PubMed Web of Science ®Google Scholar
• Erdmann E, Charbonnel B, Wilcox RG, et al. PROactive Investigators. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773–2778.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Giaccari A, Gallo M, et al. SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2022;32(3):529–536.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP. Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: a comment on the IRIS trial. J Diabetes Complications. 2017;31(1):1–3.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. an expert panel statement. Metabolism. 2017;71:17–32.
   PubMed Web of Science ®Google Scholar
• Papanas N, Katsiki N, Hatzitolios AI, et al. Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12(10):1457–1461.
   PubMed Web of Science ®Google Scholar
• Sinha B, Ghosal S. Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials. Sci Rep. 2020;10(1):15781.
   PubMed Web of Science ®Google Scholar
• de Jong M, van der Worp HB, van der Graaf Y, et al. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol. 2017;16(1):134.
   PubMedGoogle Scholar
• Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017;7(1):e013927.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang Y, Ji X, et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab. 2020;105(5):dgz252.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Inzucchi S, Abdul-Ghani M, et al. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16(2):133–143.
   PubMed Web of Science ®Google Scholar
• https://www.ema.europa.eu/en/documents/product-information/actos-epar-product-information_en.pdf Last accessed 28 June 2022
   Google Scholar
• Roumie CL, Min JY, McGowan L D, et al. Comparative safety of sulfonylurea and metformin monotherapy on the risk of heart failure: a cohort study. J Am Heart Assoc. 2017;6(4):e005379.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang T, Yang Z, et al. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: a population-based cohort study in China. Pharmacoepidemiol Drug Saf. 2020;29(6):635–643.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu HY, Chien KL. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: a nationwide cohort study of patients with type 2 diabetes. Diabetes Metab. 2021;48(3):101299.
   PubMed Web of Science ®Google Scholar
• Varas-Lorenzo C, Margulis AV, Pladevall M, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord. 2014;14:129.
   PubMed Web of Science ®Google Scholar
• Khan MS, Solomon N, DeVore AD, et al. Clinical outcomes with metformin and sulfonylurea therapies among patients with heart failure and diabetes. JACC Heart Fail. 2022;10(3):198–210.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Kotsa K, Stoian AP, et al. Hypoglycaemia and cardiovascular disease risk in patients with diabetes. Curr Pharm Des. 2020;26(43):5637–5649.
   PubMed Web of Science ®Google Scholar
• Savarese G, Schrage B, Cosentino F, et al. Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. ESC Heart Fail. 2020;7(6):3438–3451.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 steering committee and investigators. saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. SAVOR-TIMI 53 steering committee and investigators*. heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–1588.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-adds-warnings-about-heart-failure-risk-labels-type-2-diabetes Last accessed 28 June 2022
   Google Scholar
• Toh S, Hampp C, Reichman ME, et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med. 2016;164(11):705–714.
   PubMed Web of Science ®Google Scholar
• TECOS Study Group, Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA investigators. effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Kahn SE, Johansen OE, et al. CAROLINA investigators. effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–1166.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Ponikowski P, Bolli GB, et al. VIVIDD trial committees and investigators. effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018;6(1):8–17.
   PubMed Web of Science ®Google Scholar
• Packer M. Worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications. JACC Heart Fail. 2018;6(6):445–451. .
   PubMed Web of Science ®Google Scholar
• Koska J, Sands M, Burciu C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12(3):154–163.
   PubMed Web of Science ®Google Scholar
• Pan X, Xu S, Li J, et al. The effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 inhibitors on heart failure outcomes in diabetic patients with and without heart failure history: insights from CVOTs and drug mechanism. Front Endocrinol (Lausanne). 2020;11:599355.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Nreu B, Montereggi C, et al. SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021;31(10):2745–2755.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Longo M, et al. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. Endocrine. 2019;65(1):15–24.
   PubMed Web of Science ®Google Scholar
• Xu L, Zheng XQ, Liao XX. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis based on propensity score-matched studies. Prim Care Diabetes. 2022;16(1):207–210.
   PubMed Web of Science ®Google Scholar
• Khan MS, Fonarow GC, McGuire DK, et al. Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization. Circulation. 2020;142(12):1205–1218.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER steering committee; LEADER trial investigators. liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. ELIXA investigators. lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.
   PubMed Web of Science ®Google Scholar
• EXSCEL Study Group, Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377(13):1228–1239.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 investigators. semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. PIONEER 6 investigators. oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851.
   PubMed Web of Science ®Google Scholar
• https://clinicaltrials.gov/ct2/show/NCT03914326 Last accessed 28 June 2022
   Google Scholar
• Fudim M, White J, Pagidipati NJ, et al. Effect of once-weekly exenatide in patients with type 2 Diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation. 2019;140(20):1613–1622.
   PubMed Web of Science ®Google Scholar
• Marso SP, Baeres FMM, Bain SC, et al. LEADER trial investigators. effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2020;75(10):1128–1141.
   PubMed Web of Science ®Google Scholar
• Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442–451.
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529.
   PubMed Web of Science ®Google Scholar
• Lepore JJ, Olson E, Demopoulos L, et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail. 2016;4(7):559–566.
   PubMed Web of Science ®Google Scholar
• Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69–77.
   PubMed Web of Science ®Google Scholar
• Margulies KB, Hernandez AF, Redfield MM, et al. NHLBI heart failure clinical research network. effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316(5):500–508.
   PubMed Web of Science ®Google Scholar
• Balestrieri ML, Rizzo MR, Barbieri M, et al. Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. Diabetes. 2015;64(4):1395–1406.
   PubMed Web of Science ®Google Scholar
• Sardu C, Paolisso P, Sacra C, et al. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate. Cardiovasc Diabetol. 2018;17(1):137.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• CANVAS Program Collaborative Group, Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 investigators. dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. VERTIS CV investigators. cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019;139(25):2822–2830.
   PubMed Web of Science ®Google Scholar
• CVD-REAL Investigators and Study Group, Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 2017;136(3):249–259.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. SOLOIST-WHF trial investigators. sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353–1368.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. EMPEROR-reduced trial investigators. cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. EMPEROR-preserved trial investigators. empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461.
   PubMed Web of Science ®Google Scholar
• Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568–574.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Qintar M, Windsor SL, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673–1686.
   PubMed Web of Science ®Google Scholar
• Verma S, Mazer CD, Yan AT, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART cardiolink-6 randomized clinical trial. Circulation. 2019;140(21):1693–1702.
   PubMed Web of Science ®Google Scholar
• Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516–525.
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. EMPA-TROPISM (ATRU-4) investigators. randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–255.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021;27(11):1954–1960.
   PubMed Web of Science ®Google Scholar
• Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140(18):1463–1476.
   PubMed Web of Science ®Google Scholar
• Singh JSS, Mordi IR, Vickneson K, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM trial. Diabetes Care. 2020;43(6):1356–1359.
   PubMed Web of Science ®Google Scholar
• Zhang N, Wang Y, Tse G, et al. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28(17):1961–1973.
   PubMed Web of Science ®Google Scholar
• Camilli M, Lombardi M, Chiabrando JG, et al. Sodium-glucose cotransporter inhibitors reduce mortality and morbidity in patients with heart failure: evidence from a meta-analysis of randomized trials. Am J Ther. 2021;29(2):e199–e204.
   PubMed Web of Science ®Google Scholar
• Salah HM, Al’Aref SJ, Khan MS, et al., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):20.
   PubMed Web of Science ®Google Scholar
• Pandey AK, Dhingra NK, Hibino M, et al., Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Fail. 2022;9(2):942–946.
   PubMed Web of Science ®Google Scholar
• Chen C, Peng H, Li M, et al. Patients with type 2 diabetes mellitus and heart failure benefit more from sodium-glucose cotransporter 2 inhibitor: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:664533.
   PubMed Web of Science ®Google Scholar
• Shrestha DB, Budhathoki P, Sedhai YR, et al. Sodium-glucose cotransporter-2 inhibitors in heart failure: an updated systematic review and meta-analysis of 13 randomized clinical trials including 14,618 patients with heart failure. J Cardiovasc Pharmacol. 2021;78(4):501–514.
   PubMed Web of Science ®Google Scholar
• Lam CSP, Chandramouli C, Ahooja V, et al. SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019;8(20):e013389.
   PubMed Web of Science ®Google Scholar
• Muzurović E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opin Pharmacother. 2020;21(17):2125–2135.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Kotsa K, Kotsis V. Empagliflozin effects on cardiac remodeling: re-shaping the future of heart failure prevention. Expert Rev Cardiovasc Ther. 2020;18(11):841–842.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Theodorakis MJ. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): their role in cardiometabolic risk management. Curr Pharm Des. 2017;23(10):1522–1532.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP. Iron absorption, bone marrow fat and hematopoiesis in heart failure: additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)? J Diabetes Complications. 2019;33(11):107408.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Triposkiadis F. Resistance to diuretics in heart failure: any role for empagliflozin? Curr Vasc Pharmacol. 2019;17(4):421–424.
   PubMed Web of Science ®Google Scholar
• Batzias K, Antonopoulos AS, Oikonomou E, et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis. J Diabetes Res. 2018;2018:1232583.
   PubMed Web of Science ®Google Scholar
• Marfella R, D’Onofrio N, Trotta MC, et al. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2022;127:154936.
   PubMed Web of Science ®Google Scholar
• Paolisso P, Bergamaschi L, Santulli G, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21(1):77.
   PubMed Web of Science ®Google Scholar
• Sardu C, Massimo Massetti M, Rambaldi P, et al. SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study. Metabolism. 2022;155243. 10.1016/j.metabol.2022.155243
   PubMedGoogle Scholar
• D’Onofrio N, Sardu C, Trotta MC, et al. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of sodium-glucose co-transporter2 inhibitor treatment. Mol Metab. 2021;54:101337.
   PubMed Web of Science ®Google Scholar
• Sardu C, Massetti M, Testa N, et al. Effects of sodium-glucose transporter 2 inhibitors (SGLT2-I) in patients with Ischemic Heart Disease (IHD) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up. Front Pharmacol. 2021;12:777083.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Dimitriadis G, Hahalis G, et al. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence. Metabolism. 2019;96:92–100.
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/drugs/drug-safety-and-availability/fda- removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin Last accessed 28 June 2022
   Google Scholar
• https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure Last accessed 28 June 2022
   Google Scholar
• https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga Last accessed 28 June 2022
   Google Scholar
• https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure Last accessed 28 June 2022
   Google Scholar
• Cosmi F, Shen L, Magnoli M, et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail. 2018;20(5):888–895.
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4):319–328.
   PubMed Web of Science ®Google Scholar
• DEVOTE Study Group, Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377(8):723–732.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Jung H, Rydén L, et al. ORIGIN investigators. effect of basal insulin glargine on first and recurrent episodes of heart failure hospitalization: the ORIGIN trial (outcome reduction with initial glargine intervention). Circulation. 2018;137(1):88–90.
   PubMed Web of Science ®Google Scholar
• DEVOTE Study Group, Pratley RE, Husain M, Lingvay I, et al. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol 2019;18(1):156.
   PubMed Web of Science ®Google Scholar
• Chen TH, Wang CC, Liu CH, et al. Similar cardiovascular outcomes between insulin detemir and insulin glargine in type 2 diabetic patients with extremely atherosclerotic cardiovascular disease risks. Endocr Pract. 2020;26(8):818–829.
   PubMed Web of Science ®Google Scholar
• Liu J, Hu X. Impact of insulin therapy on outcomes of diabetic patients with heart failure: a systematic review and meta-analysis. Diab Vasc Dis Res. 2022;19(3):14791641221093175.
   Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. TOPCAT investigators. spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392.
   PubMed Web of Science ®Google Scholar
• Huynh T, Harty BJ, Claggett B, et al. Comparison of outcomes in patients with diabetes mellitus treated with versus without insulin + heart failure with preserved left ventricular ejection fraction (from the TOPCAT study). Am J Cardiol. 2019;123(4):611–617.
   PubMed Web of Science ®Google Scholar
• Staszewsky L, Baviera M, Tettamanti M, et al. Insulin treatment in patients with diabetes mellitus and heart failure in the era of new antidiabetic medications. BMJ Open Diabetes Res Care. 2022;10(2):e002708.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh R. Effect of background insulin therapy on cardiovascular outcomes with SGLT-2 inhibitors in type 2 diabetes: a meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract. 2021;172:108648.
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members, Ponikowski P, Voors AA, Anker SD, et al. Document reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Eberly LA, Yang L, Eneanya ND, et al. Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US. JAMA Network Open. 2021;4(4):e216139.
   PubMed Web of Science ®Google Scholar
• Lee DSU, Lee H. Adherence and persistence rates of major antidiabetic medications: a review. Diabetol Metab Syndr. 2022;14(1):12.
   PubMed Web of Science ®Google Scholar